Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709852 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00709852 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 402 participants.
The verdict
NCT00709852, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadavist) Injection and ProHance Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance.
Interventions
- DRUG Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- DRUG Gadoteridol (ProHance)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00709852
The ClinicalTrials.gov registry entry for NCT00709852 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gadobutrol (Gadavist, Gadovist, BAY86-4875) is the first listed.
NCT00709852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00709852 about?
NCT00709852 is a clinical study titled "Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging". This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadavist) Injection and ProHance Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR ima...
What is the current status of trial NCT00709852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2008-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00709852?
The interventions under investigation include: Gadobutrol (Gadavist, Gadovist, BAY86-4875) (DRUG), Gadoteridol (ProHance) (DRUG).
Who is sponsoring clinical trial NCT00709852?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.